Work

Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.531

Authors: Tanya Jindal, Li Zhang, Jonathan Chou, David Shui, Sima P. Porten, Anthony C. Wong, Emily Chan, Bradley A. Stohr, Ivan de Kouchkovsky, Hala Borno, Rohit Bose, Daniel H Kwon, Arpita Desai, Franklin W. Huang, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4213061322

Cites:

Cited by: 4

Related to: 10